Unknown

Dataset Information

0

Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody.


ABSTRACT: Therapy of melanoma using T-cells with genetically introduced T-cell receptors (TCRs) directed against a tumor-selective cancer testis antigen (CTA) NY-ESO1 demonstrated clear antitumor responses in patients without side effects. Here, we exploited the concept of TCR-mediated targeting through introduction of single-chain variable fragment (scFv) antibodies that mimic TCRs in binding major histocompatibility complex-restricted CTA. We produced scFv antibodies directed against Melanoma AntiGEn A1 (MAGE A1) presented by human leukocyte antigen A1 (HLA-A1), in short M1/A1, and coupled these TCR-like antibodies to liposomes to achieve specific melanoma targeting. Two anti-M1/A1 antibodies with different ligand-binding affinities were derived from a phage-display library and reformatted into scFvs with an added cysteine at their carboxyl termini. Protein production conditions, ie, bacterial strain, temperature, time, and compartments, were optimized, and following production, scFv proteins were purified by immobilized metal ion affinity chromatography. Batches of pure scFvs were validated for specific binding to M1/A1-positive B-cells by flow cytometry. Coupling of scFvs to liposomes was conducted by employing different conditions, and an optimized procedure was achieved. In vitro experiments with immunoliposomes demonstrated binding of M1/A1-positive B-cells as well as M1/A1-positive melanoma cells and internalization by these cells using flow cytometry and confocal microscopy. Notably, the scFv with nonenhanced affinity of M1/A1, but not the one with enhanced affinity, was exclusively bound to and internalized by melanoma tumor cells expressing M1/A1. Taken together, antigen-mediated targeting of tumor cells as well as promoting internalization of nanoparticles by these tumor cells is mediated by TCR-like scFv and can contribute to melanoma-specific targeting.

SUBMITTER: Saeed M 

PROVIDER: S-EPMC4792179 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody.

Saeed Mesha M   van Brakel Mandy M   Zalba Sara S   Schooten Erik E   Rens Joost A P JA   Koning Gerben A GA   Debets Reno R   Ten Hagen Timo L M TL  

International journal of nanomedicine 20160308


Therapy of melanoma using T-cells with genetically introduced T-cell receptors (TCRs) directed against a tumor-selective cancer testis antigen (CTA) NY-ESO1 demonstrated clear antitumor responses in patients without side effects. Here, we exploited the concept of TCR-mediated targeting through introduction of single-chain variable fragment (scFv) antibodies that mimic TCRs in binding major histocompatibility complex-restricted CTA. We produced scFv antibodies directed against Melanoma AntiGEn A1  ...[more]

Similar Datasets

| S-EPMC2708021 | biostudies-literature
| S-EPMC8252751 | biostudies-literature
| S-EPMC3287115 | biostudies-literature
| S-EPMC3581823 | biostudies-literature
2024-03-30 | PXD048297 | Pride
2024-04-02 | PXD048298 | Pride
2024-03-30 | PXD048294 | Pride
2024-03-30 | PXD048295 | Pride
| S-EPMC8741448 | biostudies-literature
| S-EPMC8344738 | biostudies-literature